The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AUCtox: A new method to evaluate the safety of anticancer drugs.
 
Vincent Launay-Vacher
Honoraria - Amgen; Bayer; Merck; MSD Oncology; Pierre Fabre; Roche; Sandoz; Takeda; Tesaro
Consulting or Advisory Role - Onxeo; Pierre Fabre; Tesaro
Research Funding - Bayer (Inst); Pierre Fabre (Inst); Roche (Inst); Teva (Inst)
 
Carole Helissey
No Relationships to Disclose
 
Brigitte Laguerre
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; novartis; pfizer; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Janssen Oncology; Janssen Oncology; novartis; pfizer; pfizer
 
Dominique Spaeth
No Relationships to Disclose
 
Thomas Lloret
Research Funding - Sanofi (Inst)
 
Jerome Stevens
Research Funding - Sanofi (Inst)
 
Paolo Bossi
Honoraria - Kyowa Hakko Kirin; MSD Oncology; Prostrakan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Helsinn Therapeutics; Merck Serono; Mundipharma; Tesaro
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Helsinn Therapeutics (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
 
Florian Scotte
Honoraria - Amgen; Helsinn Healthcare; Leo Pharma; MSD; Pfizer; Pierre Fabre; Roche; Vifor Pharma
Consulting or Advisory Role - MSD; Pierre Fabre; Roche; Tesaro; Vifor Pharma